US Patent Issued to Cellectis on Oct. 27 for "Methods for improving functionality in NK cell by gene inactivation using specific endonuclease" (French, American Inventors)

ALEXANDRIA, Va., Oct. 27 -- United States Patent no. 12,774,451, issued on Oct. 27, was assigned to Cellectis (Paris).

"Methods for improving functionality in NK cell by gene inactivation using specific endonuclease" was invented by Philippe Duchateau (Draveil, France), Jean-Pierre Cabaniols (Saint Lau la Foret, France) and Julien Valton (New York).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to methods for improving therapeutic activity of NK cell, such as their cytotoxic/cytolytic activity, to be used in immunotherapy, by gene editing. In particular, these methods comprise a step of reduction or inactivation of gene expression using specific endonuclease such as TAL-nuclease,...